

February 02, 2018

To,

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai - 400 051.

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers
Dalal Street
Mumbai 400 001

Symbol: RPGLIFE

Scrip code: 532983

Dear Sir/Madam,


Sub: Press Release-Financial Results

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter ended December 31, 2017.

Kindly take the above on record.

Thanking you,

Yours faithfully,
For RPG Life Sciences Limited



Rajesh Shirambekar
Head - Legal & Company Secretary



Encl: As above



RPG Life Sciences reports robust Q3FY18 revenue and profit growth

- Revenue grows 38% YoY
- PBT grows 6.3x YoY

Mumbai, 2 February, 2018: RPG Life Sciences Limited has announced its unaudited financial results for the quarter ending December 31st, 2017.

Q3 FY18 Highlights	YoY Net Revenue from Operations	YoY PBT from Operations
	Rs 95.66 crores – up from Rs 69.16 crores	Rs 8.00 crores – up from Rs 1.10 crores

RPG Life Sciences, engaged in manufacturing and marketing of pharmaceutical products, posted a robust increase in revenue at Rs. 95.66 crores which is a 38% increase as against Rs. 69.16 crores posted in Q3FY17. The company's PBT stood at Rs 8.00 crores for the quarter as against Rs. 1.10 crores in Q3FY17 which is a substantial 627% jump.

On a Q-o-Q basis the company's PBT from operations grew from Rs 7.5 crores to Rs 8.00 crores and the Net Revenue from Operations grew from Rs 89.51 crores to Rs 95.66 crores.

“During the quarter we have seen significant growth in the topline driven by robust growth across domestic and international businesses. In the domestic formulations segment, we witnessed strong growth across main, nephrology and Neolife sales aided by strong pick-up in new products launched during the previous quarters. In the international formulations segment, our global generics sales saw robust performance. Our API business segment grew exceptionally well during the quarter, delivering all-time high sales and profitability. We have successfully recovered from GST impact and expect to maintain higher-than-industry growth momentum going forward” said CT Renganathan, Managing Director, RPG Life Sciences Ltd.

Q3 FY18 Other Highlights	1. EDITDA margins improved from 7.7% to 13.1%
	2. Domestic formulation grew by 37%
	3. Global Generic business grew by 192%
	4. API grew by 57%

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

Mumbai head-quartered RPG Enterprises is one of India's largest industrial conglomerates. With over 15 companies in its fold, the group has a strong presence across core business sectors such as Infrastructure, Tyre, IT and Specialty. Established in 1979, RPG Enterprises is one of India's fastest growing business groups with a turnover in excess of Rs 21,000 crore.

Media Contact:

Sumeet Chatterjee

Senior Vice President – Group Communications

sumeet@rpg.in

+91 9820340650

